TY - JOUR
T1 - Cardiac T2∗ measurement of hyperpolarized 13C metabolites using metabolite-selective multi-echo spiral imaging
AU - Ma, Junjie
AU - Chen, Jun
AU - Reed, Galen D.
AU - Hackett, Edward P.
AU - Harrison, Crystal E.
AU - Ratnakar, James
AU - Schulte, Rolf F.
AU - Zaha, Vlad G.
AU - Malloy, Craig R.
AU - Park, Jae Mo
N1 - Funding Information:
Supported by The National Institutes of Health (NIH) grants (P41 EB015908, S10 RR029119, S10 OD018468, R01 NS107409); The Welch Foundation grants (I‐2009‐20190330); the UT Dallas Collaborative Biomedical Research Award (CoBRA) (UTD 1907789); The Cancer Prevention and Research Institute of Texas (CPRIT) grant (RP180404). The Texas Institute for Brain Injury and Repair (TIBIR)
Funding Information:
Supported by The National Institutes of Health (NIH) grants (P41 EB015908, S10 RR029119, S10 OD018468, R01 NS107409); The Welch Foundation grants (I-2009-20190330); the UT Dallas Collaborative Biomedical Research Award (CoBRA) (UTD 1907789); The Cancer Prevention and Research Institute of Texas (CPRIT) grant (RP180404). The Texas Institute for Brain Injury and Repair (TIBIR) Personnel Support. We appreciate the clinical research team and the supporting staffs of the Advanced Imaging Research Center at UT Southwestern for imaging the volunteers: Jeff Liticker, PharmD, Ronald G. Hall, PharmD, Jaffar Raza, PharmD, Jeannie Baxter, RN, Kelley Derner, RN, Salvador Pena, Corey Mozingo, Maida Tai, and Richard Martin.
Publisher Copyright:
© 2021 International Society for Magnetic Resonance in Medicine
PY - 2021/9
Y1 - 2021/9
N2 - Purpose: Noninvasive imaging with hyperpolarized (HP) pyruvate can capture in vivo cardiac metabolism. For proper quantification of the metabolites and optimization of imaging parameters, understanding MR characteristics such as (Formula presented.) s of the HP signals is critical. This study is to measure in vivo cardiac (Formula presented.) s of HP [1-13C]pyruvate and the products in rodents and humans. Methods: A dynamic 13C multi-echo spiral imaging sequence that acquires [13C]bicarbonate, [1-13C]lactate, and [1-13C]pyruvate images in an interleaved manner was implemented for a clinical 3 Tesla system. (Formula presented.) of each metabolite was calculated from the multi-echo images by fitting the signal decay of each region of interest mono-exponentially. The performance of measuring (Formula presented.) using the sequence was first validated using a 13C phantom and then with rodents following a bolus injection of HP [1-13C]pyruvate. In humans, (Formula presented.) of each metabolite was calculated for left ventricle, right ventricle, and myocardium. Results: Cardiac (Formula presented.) s of HP [1-13C]pyruvate, [1-13C]lactate, and [13C]bicarbonate in rodents were measured as 24.9 ± 5.0, 16.4 ± 4.7, and 16.9 ± 3.4 ms, respectively. In humans, (Formula presented.) of [1-13C]pyruvate was 108.7 ± 22.6 ms in left ventricle and 129.4 ± 8.9 ms in right ventricle. (Formula presented.) of [1-13C]lactate was 40.9 ± 8.3, 44.2 ± 5.5, and 43.7 ± 9.0 ms in left ventricle, right ventricle, and myocardium, respectively. (Formula presented.) of [13C]bicarbonate in myocardium was 64.4 ± 2.5 ms. The measurements were reproducible and consistent over time after the pyruvate injection. Conclusion: The proposed metabolite-selective multi-echo spiral imaging sequence reliably measures in vivo cardiac (Formula presented.) s of HP [1-13C]pyruvate and products.
AB - Purpose: Noninvasive imaging with hyperpolarized (HP) pyruvate can capture in vivo cardiac metabolism. For proper quantification of the metabolites and optimization of imaging parameters, understanding MR characteristics such as (Formula presented.) s of the HP signals is critical. This study is to measure in vivo cardiac (Formula presented.) s of HP [1-13C]pyruvate and the products in rodents and humans. Methods: A dynamic 13C multi-echo spiral imaging sequence that acquires [13C]bicarbonate, [1-13C]lactate, and [1-13C]pyruvate images in an interleaved manner was implemented for a clinical 3 Tesla system. (Formula presented.) of each metabolite was calculated from the multi-echo images by fitting the signal decay of each region of interest mono-exponentially. The performance of measuring (Formula presented.) using the sequence was first validated using a 13C phantom and then with rodents following a bolus injection of HP [1-13C]pyruvate. In humans, (Formula presented.) of each metabolite was calculated for left ventricle, right ventricle, and myocardium. Results: Cardiac (Formula presented.) s of HP [1-13C]pyruvate, [1-13C]lactate, and [13C]bicarbonate in rodents were measured as 24.9 ± 5.0, 16.4 ± 4.7, and 16.9 ± 3.4 ms, respectively. In humans, (Formula presented.) of [1-13C]pyruvate was 108.7 ± 22.6 ms in left ventricle and 129.4 ± 8.9 ms in right ventricle. (Formula presented.) of [1-13C]lactate was 40.9 ± 8.3, 44.2 ± 5.5, and 43.7 ± 9.0 ms in left ventricle, right ventricle, and myocardium, respectively. (Formula presented.) of [13C]bicarbonate in myocardium was 64.4 ± 2.5 ms. The measurements were reproducible and consistent over time after the pyruvate injection. Conclusion: The proposed metabolite-selective multi-echo spiral imaging sequence reliably measures in vivo cardiac (Formula presented.) s of HP [1-13C]pyruvate and products.
KW - T 2 ∗
KW - dynamic nuclear polarization
KW - heart
KW - hyperpolarized pyruvate
KW - multi-echo spiral imaging
UR - http://www.scopus.com/inward/record.url?scp=85103588007&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103588007&partnerID=8YFLogxK
U2 - 10.1002/mrm.28796
DO - 10.1002/mrm.28796
M3 - Article
C2 - 33821504
AN - SCOPUS:85103588007
VL - 86
SP - 1494
EP - 1504
JO - Magnetic Resonance in Medicine
JF - Magnetic Resonance in Medicine
SN - 0740-3194
IS - 3
ER -